5 research outputs found

    Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review.

    Get PDF
    Despite their potential to prevent or delay the onset and progression of cardiovascular disease (CVD), medicines for CVD remain unavailable and unaffordable to many in low- and middle-income countries (LMICs). We systematically reviewed the literature to identify factors associated with availability and affordability of CVD medicines in LMICs. A protocol for this study was registered on the PROSPERO register of systematic reviews (CRD42019135393). We searched Medline, EMBASE, Global Health, Cumulative Index to Nursing and Allied Health Literature, EconLit, Social Policy and Practice, and Africa Wide Information for studies analyzing factors associated with the presence of medicines (availability) or the price of these medicines as it relates to ability to pay (affordability) in LMICs. We performed a narrative synthesis of the results using an access to medicines framework that examines influences at different levels of the health system. We did not conduct a meta-analysis because of the differences in analytic approaches and outcome measures in different studies. The search was conducted in accordance with PRISMA guidelines. Of 43 studies meeting inclusion criteria, 41 were cross-sectional. Availability and affordability were defined and measured in different ways. A range of factors such as sociodemographic characteristics, facility tier, presence of medicines on national essential medicine lists, and international subsidy programs were examined. The studies had variable quality and findings were often inconsistent. We find gaps in the literature on factors associated with availability and affordability of CVD medicines, particularly at the health program level. We conclude that there is a need for experimental and quasi-experimental studies that could identify causal factors and effective responses. Such studies would help further our understanding of how complex multifactorial influences impact these outcomes, which could inform policy decisions. Along with this, greater standardization of definitions and measurement approaches of availability and affordability are needed to allow for more effective comparisons

    COACHing for COVID: A Qualitative Assessment of Incorporating Community Health Workers into Primary Care-Based COVID-19 Outreach

    Get PDF
    Context/background: In July 2020, recognizing the potential negative interaction between COVID-19 quarantine and medical and social needs, Oregon Health & Science University Family Medicine at Richmond developed a workflow to support clinic patients with acute social and medical needs who test positive for COVID-19. The workflow relies on Community Health Workers (CHWs) who call these patients and ask questions intended to identify social and medical needs. Within this workflow, patients with identified needs are connected by CHWs to community resources. The workflow is intended to reduce barriers to patients’ ability to maintain isolation while adhering to physical distancing guidelines, and to help patients address social determinants of health (SDH). Objective: Develop a comprehensive understanding of the design, implementation, and maintenance of the workflow via key informant interviews, with the goal of creating guidance for other primary care practices interested in developing a similar workflow. Methods: This was a qualitative study conducted in a federally qualified health center housed in the department of family medicine at an academic health center. Key informant interviews were conducted with six personnel involved in developing the workflow. Using a semi-structured interview guide, evaluators asked participants about processes, barriers, and facilitators involved with design, implementation, and maintenance of the workflow. Participants were also asked to provide their assessment of the workflow’s impact on patients, the clinic, and the healthcare system. Interviews were analyzed using an immersion-crystallization approach. Results: Prominent themes associated with the workflow’s development included adaptability, content expertise, data, environmental unpredictability, funding, staff bandwidth, lack of coordination across the system, patient centeredness and whole-person care. Perceptions of the workflow’s impact most commonly related to its effects on the relationship between patients and the healthcare system. Across all project phases (design, implementation, and maintenance), adaptability and content expertise were reported to be essential for success. The main barrier across project phases was lack of coordination across the system. Delivery of whole-person care was felt to be the primary benefit to both patients and the healthcare system. Conclusions: Personnel from a variety of disciplines expressed that integration of CHWs into COVID-19 outreach was beneficial to both patients and the primary care practice. For other practices interested in implementing such a workflow, key informants identified themes for success including a project framework built on patient-centeredness, adaptability and the unique content expertise of CHWs. Across all project phases, adaptability was a prominent facilitator while lack of system coordination was a prominent barrier. Overall, the workflow was felt to be beneficial to the patient-system relationship, the most common reason being the workflow’s emphasis on providing whole-person care

    Factors associated with the availability and affordability of essential cardiovascular disease medicines in low- and middle-income countries: A systematic review. Data extraction table.

    No full text
    Despite their potential to prevent or delay the onset and progression of cardiovascular disease (CVD), medicines for CVD remain unavailable and unaffordable to many in low- and middle-income countries (LMICs). We systematically reviewed the literature to identify factors associated with availability and affordability of CVD medicines in LMICs. A protocol for this study was registered on the PROSPERO register of systematic reviews (CRD42019135393). We searched Medline, EMBASE, Global Health, Cumulative Index to Nursing and Allied Health Literature, EconLit, Social Policy and Practice, and Africa Wide Information for studies analyzing factors associated with the presence of medicines (availability) or the price of these medicines as it relates to ability to pay (affordability) in LMICs. We performed a narrative synthesis of the results using an access to medicines framework that examines influences at different levels of the health system. We did not conduct a meta-analysis because of the differences in analytic approaches and outcome measures in different studies. The search was conducted in accordance with PRISMA guidelines. Of 43 studies meeting inclusion criteria, 41 were cross-sectional. Availability and affordability were defined and measured in different ways. A range of factors such as sociodemographic characteristics, facility tier, presence of medicines on national essential medicine lists, and international subsidy programs were examined. The studies had variable quality and findings were often inconsistent. We find gaps in the literature on factors associated with availability and affordability of CVD medicines, particularly at the health program level. We conclude that there is a need for experimental and quasi-experimental studies that could identify causal factors and effective responses. Such studies would help further our understanding of how complex multifactorial influences impact these outcomes, which could inform policy decisions. Along with this, greater standardization of definitions and measurement approaches of availability and affordability are needed to allow for more effective comparisons

    Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS-CoV-2.

    No full text
    SARS-CoV-2 is an emerging viral pathogen and a major global public health challenge since December of 2019, with limited effective treatments throughout the pandemic. As part of the innate immune response to viral infection, type I interferons (IFN-I) trigger a signaling cascade that culminates in the activation of hundreds of genes, known as interferon stimulated genes (ISGs), that collectively foster an antiviral state. We report here the identification of a group of type I interferon suppressed genes, including fatty acid synthase (FASN), which are involved in lipid metabolism. Overexpression of FASN or the addition of its downstream product, palmitate, increased viral infection while knockout or knockdown of FASN reduced infection. More importantly, pharmacological inhibitors of FASN effectively blocked infections with a broad range of viruses, including SARS-CoV-2 and its variants of concern. Thus, our studies not only suggest that downregulation of metabolic genes may present an antiviral strategy by type I interferon, but they also introduce the potential for FASN inhibitors to have a therapeutic application in combating emerging infectious diseases such as COVID-19
    corecore